Blogs

PQRI Position Paper "Is there a Case for Banning Titanium Dioxide (E171) in Pharmaceuticals?"

By Kim Beals posted 28 days ago

  

A PQRI Workshop held in June 2023 in Washington DC, explored the feasibility of replacement of titanium dioxide from a technical and regulatory point of view. World-class experts examined the safety of titanium dioxide, its potential replacements and what its ban would mean for the availability of medicines in Europe which are predicted to be severely affected should such a ban come into force. This paper describes the findings from the workshop. Visit the Public Library to download the paper.